ライフサイエンスコーパス: vascular stiffness

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 and whether this contributes to age-related vascular stiffness.

2 w-density lipoprotein-dependent increases in vascular stiffness.

3 lastin and collagen, potentially influencing vascular stiffness.

4 that L-arginine has the potential to reduce vascular stiffness.

5 Aortic pulse-wave velocity measured vascular stiffness.

6 duction of ventricular systolic and arterial vascular stiffnesses.

7 tension is predominantly systolic because of vascular stiffness; (2) it is associated with reduced ba

8 Vascular stiffness and blood pressure pulsatility are re

9 Dysregulation of vascular stiffness and cellular metabolism occurs early

10 sodium restriction improves ventricular and vascular stiffness and function.

11 hrombin generation, cardiac dysfunction, and vascular stiffness and identified incident AAAs during f

12 sent a therapeutic target for age-associated vascular stiffness and isolated systolic hypertension.

13 ships among blood pressure and 3 measures of vascular stiffness and pressure pulsatility derived from

14 of PH, pharmacologic modulation of pulmonary vascular stiffness and YAP-dependent mechanotransduction

15 such as aneurysm formation, arterial aging, vascular stiffness, and chronic venous disease, even tho

16 enrolled, change in noninvasive measures of vascular stiffness, and clinical events.

17 opment of vasodilator dysfunction, increased vascular stiffness, and elevated blood pressure at a ver

18 We assessed vascular stiffness at baseline, after 3 to 6 weeks of th

19 iminary evidence that lonafarnib may improve vascular stiffness, bone structure, and audiological sta

20 ammation, endothelial dysfunction, increased vascular stiffness, changes in vascular structure, and a

21 mal responses to flow and NTG, and increased vascular stiffness confined to the upper part of the bod

22 Intima-media thickness (IMT) and vascular stiffness have been shown to be independent pre

23 Furthermore, TG2 inhibition decreases vascular stiffness in aging rats.

24 ular remodeling, and associated increases in vascular stiffness in females.

25 al remodelling on vascular contractility and vascular stiffness in health and disease.

26 lieved to increase left ventricular (LV) and vascular stiffness, in part via cross-linking proteins.

27 on, whereas the risk factors associated with vascular stiffness include SLE-specific variables relate

28 Measures of vascular stiffness increased significantly during the pe

29 Vascular stiffness increases with advancing age and is a

30 Baseline vascular stiffness, indexed by arterial pulse-wave veloc

31 asminogen activator inhibitor-1 with central vascular stiffness indices, and C-reactive protein with

32 As a result, vascular stiffness is a key driver of (chronic) human di

33 Vascular stiffness is a mechanical property of the vesse

34 he groups as a whole, mitigated increases in vascular stiffness measured by PWA (P = 0.0065) and redu

35 d postinfarction therapies, does not improve vascular stiffness measurements or ejection fraction and

36 cant change from baseline to 6 months in the vascular stiffness measurements or left ventricular ejec

37 Baseline characteristics, vascular stiffness measurements, and left ventricular fu

38 rential influences of biological pathways on vascular stiffness measures.

39 osterone system activation with pan-arterial vascular stiffness, plasminogen activator inhibitor-1 wi

40 ain rates, suggesting borderline disease and vascular stiffness, respectively.

41 Concurrently, vascular stiffness was assessed using pulse wave velocit

42 Vascular stiffness was evaluated using simultaneous caro

43 Vascular stiffness was measured by carotid-femoral pulse

44 ns in human DNA repair genes and markers for vascular stiffness, which is associated with aging.

45 , not appreciated previously, that increased vascular stiffness with aging is attributable not only t

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。